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Abstract 
Background: A clinically relevant bleeding diathesis is a frequent diagnostic 
challenge, which sometimes remains unexplained despite extensive investigations. 
The aim of our work was to evaluate the diagnostic utility of functional platelet testing 
by flow cytometry in this context.  
Methods: In case of negative results after standard laboratory work-up, flow 
cytometric analysis (FCA) of platelet function was done. We performed analysis of 
surface glycoproteins (GP) Ibα, IIb, IIIa; P-selectin expression and PAC-1 binding 
after graded doses of ADP, collagen and thrombin; content/secretion of dense 
granules; ability to generate procoagulant platelets.  
Results: Out of 437 patients investigated with standard tests between January 2007 
and December 2011, we identified 67 (15.3%) with high bleeding scores and non-
diagnostic standard laboratory work-up including platelet aggregation studies. Among 
these patients FCA revealed some potentially causative platelet defects: decreased 
dense-granule content/secretion (n=13); decreased alpha-granule secretion induced 
by ADP (n=10), convulxin (n=4) or thrombin (n=3); decreased fibrinogen-receptor 
activation induced by ADP (n=11), convulxin (n=11) or thrombin (n=8); decreased 
generation of COAT-platelets, i.e. highly procoagulant platelets induced by 
simultaneous activation with collagen and thrombin (n=16).  
Conclusion: Our work confirms that storage pool defects are frequent in patients 
with a bleeding diathesis and normal coagulation and platelet aggregations studies. 
Additionally, flow cytometric analysis is able to identify discrete platelet activation 
defects. In particular, we show for the first time that a relevant proportion of these 
patients has an isolated impaired ability to generate COAT-platelets – a conceptually 
new defect in platelet procoagulant activity, that is missed by conventional laboratory 
work-up. 
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Introduction 
A clinically relevant bleeding diathesis is a frequent diagnostic challenge and 
identification of its etiology may be difficult (1). To assess the cause of bleeding a 
comprehensive clinical evaluation and a sequential laboratory work-up are 
necessary. Accurate acquisition of medical history is the first essential step. For this 
purpose, bleeding questionnaires have been developed and validated in clinical 
practice (2,3). In addition, standard laboratory tests are helpful to detect disorders of 
primary hemostasis or coagulation factor defects (4,5). However, identification of 
clinically relevant disorders of primary hemostasis may be difficult and work-up of a 
patient with a significant bleeding diathesis fails sometimes to detect an explanatory 
cause (1). The difficulty to determine the etiology is more pronounced if the bleeding 
is caused by a platelet dysfunction. A variety of different aspects of the platelet 
function can be impaired on a genetic basis (6) and multiple factors have an impact 
on the clinical phenotype – e.g., dietary and metabolic variables, smoking, 
inflammation, drugs, and other components of the hemostatic system (7). Because 
knowledge of bleeding’s etiology is a prerequisite for optimal patient management, 
efforts to improve laboratory diagnostic procedures have been made. Presently 
various platelet function assays are available and the combination of multiple tests 
provides information about platelet function as a whole. Flow cytometric analysis is a 
very helpful tool in the diagnostic work-up of hematologic malignancies and several 
studies have shown its utility in diagnosing platelet defects as well (8-10). 
 
At our institution a standardized procedure with step by step diagnostic is applied to 
out-patients referred for clarification of a bleeding diathesis (Figure 1). Acquisition of 
a detailed medical history and clinical examination are followed by analysis of 
plasmatic coagulation factors, including von Willebrand factor and whole blood 
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assessment of primary hemostasis. If no obvious cause of hemorrhagic diathesis is 
found, diagnostic procedure is widened to investigate platelet aggregation in vitro. As 
published by Quiroga et al. (1), also in our experience extended laboratory analyses 
are not always able to determine the underlying cause of the bleeding diathesis.  
 
The aim of the present study was to evaluate the diagnostic utility of an extensive 
flow cytometric analysis of platelet function in patients with clinically relevant bleeding 
diathesis but unrevealing standard laboratory work-up.  
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Materials and Methods 
 
Patients 
Patients referred to our hematology outpatient clinic for investigation of a possible 
hemorrhagic diathesis between January 2007 and December 2011 (n = 437). During 
their first visit, the patient’s bleeding history was taken employing two bleeding score 
systems. One score is an in-house tool (University Clinic of Haematology Inselspital, 
“UCH-bleeding score”), to assess severity of bleeding at specific organs, including 
skin, nose, oral cavity, gastrointestinal, uro-genital, joints, and muscles, bleeding in 
association with minor injuries, dental procedures, and surgery, transfusion 
requirements, medications, and family history of a bleeding diathesis (maximal 26 
points; see Online Supplemental Material for details). The second score used was 
the ISTH “Bleeding score and bleeding questionnaire for the diagnosis of type 1 von 
Willebrand disease” (maximal 30 points), which has already been published some 
years ago (2). Clinical examination and standard laboratory tests including full blood 
count, global coagulation tests, all relevant coagulation factors, von Willebrand factor 
(VWF) and platelet function analyzer (PFA) were also performed at first visit. Light 
transmission platelet aggregation testing (LTA) in platelet rich plasma (PRP) and flow 
cytometric analysis (FCA) of platelet function were stepwise added, if the bleeding 
diathesis was clinically relevant and the laboratory work-up failed to reveal an 
explanatory cause (Figure 1). The study was performed in accordance with local 
regulations for diagnostic-laboratory studies (Kantonale Ethikkommission Bern, 
www.kek-bern.ch). All patients gave written informed consent. 
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Blood samples 
Blood was collected by standard venepuncture into EDTA for blood cell count 
(Monovette, Sarstedt, Nümbrecht, Germany), 0.106 M tri-sodium citrate (9:1 vol/vol) 
in plastic syringes for standard coagulation and platelet flow-cytometric assays 
(Monovette, Sarstedt, Nümbrecht, Germany), and buffered citrate for platelet 
aggregation studies (0.13 M tri-sodium citrate, pH 5.5).  
 
Analysis of coagulation parameters 
Details on coagulation assays performed in our laboratory have already been 
published (11). Clotting activities of factors VIII:C, IX:C, and XI:C were measured by 
a one stage clotting method, using factor deficient plasma (Siemens Healthcare 
Diagnostics, Marburg, Germany) and Pathromtin SL (Siemens Healthcare 
Diagnostics, Marburg), calibration curves were produced with lyophilized standard 
human plasma (SHP; Siemens Healthcare Diagnostics), the results were the average 
of 3 different sample dilutions (1:4, 1:8, 1:16). Clotting activity of factor XIII was 
measured by a chromogenic assay (Berichrom FXIII Kit, Siemens Healthcare 
Diagnostics) which was performed on a Behring Coagulation System (BCS) 
automated analyzer (Siemens Healthcare Diagnostics). Von Willebrand factor 
ristocetin cofactor activity (VWF:RCo) was measured with BC von Willebrand reagent 
(Siemens Healthcare Diagnostics) at 3 dilutions (1:4, 1:8, 1:16) using SHP for 
calibration. Von Willebrand antigen (VWF:Ag) was measured with the VIDAS VWF 
automated test system on a VIDAS analyzer (bioMérieux Suisse SA, Genève, 
Switzerland). Activity of α2-antiplasmin was measured by a chromogenic assay which 
was performed on a Behring Coagulation System (BCS) automated analyzer 
(Siemens Healthcare Diagnostics) after adding a defined amount of plasmin 
(Siemens Healthcare Diagnostics) to the patient’s sample. As a standard, plasma 
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control samples of healthy donors with a defined α2-antiplasmin concentration were 
run in parallel. 
 
Platelet function analyzer (PFA) 
The PFA is a high shear-inducing test of platelet adhesion and aggregation (12). This 
test system is sensitive to a large number of variables like platelet count and function, 
von Willebrand factor defects, and hematocrit. Therefore testing was always 
performed with knowledge of full blood count and after a 10 days wash-out period of 
any compound known to affect platelet function. The test system consists of a 
microprocessor-controlled instrument (PFA-100® and INNOVANCE® PFA-100™ 
System, Siemens Healthcare Diagnostics, Germany) and a disposable test cartridge. 
We used two types of cartridges (Dade® PFA collagen/epinephrine, and Dade® PFA 
collagen/ADP, Siemens Healthcare Diagnostics, Germany) for all patients. In 
response to stimulation by collagen, together with either epinephrine or ADP, as well 
as by high shear rates, VWF and platelets become activated and adhere on the 
membrane surface in the test cartridge. Ultimately a platelet plug gets formed, 
occludes the aperture and the blood flow is stopped. The closure times (CT) for 
epinephrine and for ADP, which are defined as the time that is required to obtain 
occlusion of the aperture, were measured in two buffered citrated whole blood 
samples of each patient.   
 
Light transmission platelet aggregation tests (LTA) in platelet rich plasma (PRP) 
LTA testing was performed as already described in the literature (13,14). Specifically, 
venous blood samples were collected into buffered 0.13 M tri-sodium citrate in a ratio 
of 1:9 (1 part anticoagulant to 9 parts blood), transported to the laboratory at room 
temperature (RT) and processed immediately. PRP was prepared by centrifugation at 
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RT for 15 minutes at 150g. The PRP was carefully removed, placed into another 
plastic tube and stored at RT. In the PRP, the platelet count was adjusted to 250 
x109/l with platelet poor plasma (PPP), prepared by further centrifugation of the 
remaining plasma at 1500g for 15 minutes at RT. In case of platelet counts between 
100 and 250 x109/l, the count was not further corrected but documented on the 
protocol. In individuals with low platelet counts below 100 x109/l an additional 
centrifugation with 150g at RT for 5 minutes was performed (15). 
 
The aggregometer (APACT 4004®, LABiTec GmbH, Ahrensburg, Germany) was 
then calibrated by using a cuvette containing PRP which equates to 0% light 
transmission and by using a second cuvette containing PPP which equates to 100% 
light transmission. Platelet aggregation was induced by increasing concentrations of 
four agonists. ADP (Sigma-Aldrich, St. Louis, MO, USA) was used at final 
concentrations of 4, 6, and 10 µM for male patients and concentrations of 3, 4, and 6 
µM for female patients. Collagen (Horm®, Nycomed, Linz, A) was used at final 
concentrations of 1.5, 3, and 4 µg/ml. Arachidonic acid (Bio Data/Medonic Servotec 
AG, Interlaken, CH) was set at 2 mM. Ristocetin (Socochim SA, Lausanne, CH) 
concentrations were 1.5 mg/ml and 0.5 mg/ml. Two-hundred µL of PRP pre-warmed 
at 37°C for 1 min was added to the aggregometer cuvette and run for an additional 
minute in order to exclude spontaneous aggregation. Thereafter, 20 µL of the agonist 
was added and the response recorded. If the response to one agonist was out of 
normal range, the test was repeated once more either to confirm the result or to rule 
out technical failures. Normally, LTA started 1 hour after having drawn the venous 
blood samples from the patient and was completed within 2.5 hours. For 
interpretation of the platelet aggregation traces we used standardized in-house 
algorithms taking into account our validation (15) and published guidelines (13,14).  
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Flow cytometric analysis of platelet function 
PRP from the patient and a normal donor was diluted to 10 x106/ml with Tyrode’s 
buffer. Analysis of surface glycoproteins (GP) Ibα (by a monoclonal anti-human 
CD42b antibody coupled with PE, Dako), GPIIb-IIIa (anti-hCD41-FITC and anti-
hCD61-FITC, Becton Dickinson), baseline P-selectin expression (anti-CD62P-PE, 
Becton Dickinson) and PAC-1 binding (PAC1-FITC, Becton Dickinson) were 
performed in a 100 µl volume containing platelets at a final concentration of 5 x106/ml 
and combinations of relevant antibodies at saturating concentrations. After incubation 
in the dark for 15 min at room temperature (RT), 1’000 µl of Tyrode’s buffer were 
added and platelets were immediately analyzed by flow cytometry (FACSCanto). 
Dose response of platelet reactivity was investigated with ADP (baseline and final 
ADP concentrations of 0.5, 5.0, and 50 µM), convulxin (5, 50, and 500 ng/ml), or 
thrombin (0.05, 0.5, and 5 nM) in a 100 µl volume containing platelets at a 
concentration of 5 x106/ml and anti-CD62P-PE and PAC1-FITC. After  incubation in 
the dark for 10 min at 37°C, 1’000 µl of Tyrode’s buffer were added to the platelets 
and the sample was analyzed immediately. Surface expression of negatively charged 
phopsholipids was investigated with Annexin V-FITC (Roche) at baseline and after 
activation for 10 min at 37°C in the dark with either 2 µM Ionophore A 23187 (Sigma) 
or the combination of 500 ng/ml convulxin and 5 nM thrombin (16). Immediately prior 
to analysis platelets were diluted with 500 µl calcium containing buffer. Finally, in 
order to evaluate content and secretion of dense granules (17), platelets were diluted 
to a final concentration of 5 x106/ml with Hank’s buffer and loaded with mepacrine 
(final 0.17 and 1.7 µM) into a 100 µl volume for 20 min at 37°C in the dark. Secretion 
of dense granule was assessed after an additional 10 min incubation at 37°C with 
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buffer versus 5 nM thrombin. Immediately prior to analysis platelets were diluted with 
1’000 µl Hank’s buffer. 
 
Flow cytometric analysis was repeated once at a later time point with different control 
platelets in order to confirm results. For P-selectin expression and GPIIb/IIIa-
activation, the reported results are the mean value of the repeated measurements 
obtained with the two highest agonist concentrations (i.e., ADP 5.0 and 50 µM; 
convulxin 50 and 500 ng/ml; thrombin 0.5 and 5 nM). When comparing the median 
fluorescence intensity (MFI) of patient platelets surface GP, dense-granule content, 
or activation endpoints (surface expression of P-selectin, PAC-1 binding) to control 
platelets we defined, based on comparisons between 40 normal subjects, in-house 
cut-offs for the lower range (see results section and table 1). The ability to generate 
procoagulant COAT platelets was described by the absolute percentage of Annexin-
V binding platelets after combined activation with convulxin 500 ng/ml and thrombin 5 
nM (16). Based on 40 control subjects we defined the ability to generate <20% COAT 
platelets as “decreased” (Table 1).  
 
Statistical analysis 
Results are expressed as median ± interquartile range (IQR), minimum-maximum 
(min-max) or mean ± standard deviation (SD). Statistical analyses were performed 
with SigmaStat (version 3.5; Systat Software Inc., San Jose, CA, USA) using non 
parametric tests. P <0.05 was considered statistically significant. 
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Results 
 
We developed an extensive flow-cytometric analysis (FCA) of platelet phenotypic and 
functional characteristics (Figures 2 and 3). Table 1 summarizes in-house cut-offs for 
phenotypic (platelet size and granularity, surface density of GPIbα, IIb, and IIIa, 
dense-granule content) and functional parameters (agonist-induced secretion of 
dense- and α-granules, activation of the fibrinogen-receptor, development of 
procoagulant COAT platelets). For most parameters we calculated relative MFI 
values compared to control platelets. As for COAT platelets, we employed the 
absolute percent values, finding results that are well in line with published data 
(16,18,19). For all parameters, in-house cut-offs for the lower range were defined 
based on the 2.5th and 5th percentile values. 
 
Here we report our experience with FCA of platelet function in 67 patients with 
unexplained clinically significant bleeding diathesis. Between January 2007 and 
December 2011, 437 patients were referred to our hematology outpatient clinic in 
order to investigate a hemorrhagic diathesis. In 67 (15.3%) of them standard 
laboratory work-up failed to identify a clear cause. The median age was 47.9 years 
(range: 16.8 – 75.4 years) and the majority were female (50/67, 75%). Median 
bleeding score was 5 both for our in-house tool (“UCH-bleeding score”, see Online 
Supplemental Material) and for the ISTH “Bleeding score and bleeding questionnaire 
for the diagnosis of type 1 von Willebrand disease” (2). Standard coagulation 
parameters and VWF-analysis were normal (Online Supplementary Table), and CT 
by PFA was either normal or un-specifically prolonged (e.g., in presence of a low 
hematocrit). Examination of LTA-PRP with different platelet agonists (ADP, collagen, 
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arachidonic acid, ristocetin) revealed in 29 patients (43%) a normal test result, 
whereas in 38 patients (57%) was abnormal (Table 1). Thirty-three patients had a 
borderline result in platelet aggregation after stimulation with ADP. Less frequently 
borderline aggregation patterns were seen after stimulation with collagen (n=27), 
arachidonic acid (n=11), and ristocetin (n=8). In 28 out of 38 individuals (74%) with 
borderline LTA-PRP, more than one agonist showed an abnormal aggregation curve. 
However, these borderline results did not allow to clearly establish the presence of a 
platelet function defect. 
 
Results of FCA are summarized in Table 2 and Figure 4. FCA did not reveal any 
defect in the surface density of the receptors for fibrinogen (GPIIb-IIIa) and VWF 
(GPIb-IX-V), and was completely normal in 18 out of the 67 (27%) patients (Table 2 
and Fig. 4). FCA of platelet function was borderline in 2 (3%) and showed abnormal 
results in 47 (70%) patients. 
 
Overall, the dense-granule content (detected by mepacrine stain) was <70% 
compared to control platelets in 9 out of 67 patients (13%): three of 29 (10%) patients 
with normal LTA-PRP and 6 of 38 (16%) patients with borderline LTA-PRP. 
Thrombin-induced secretion of dense-granules was reduced <90% in 3 patients 
(10%) with normal LTA-PRP and in 2 (5%) with borderline LTA-PRP. 
  
Secretion of α-granules (detected by P-selectin surface expression) was evaluated 
after platelet activation by graded concentrations of ADP, convulxin and thrombin. 
Among the patients with normal LTA-PRP, 5 out of 29 patients (17%) had a 
decreased α-granule secretion <40% after exposure to ADP. In contrast, only one of 
these patients showed an impaired α-granule secretion after activation with thrombin 
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(<70% compared to control platelets) and 2 after convulxin (<65%). In the cohort with 
borderline LTA-PRP, 5 out of 38 patients (13%) showed an α-granule secretion <40% 
after ADP-induced activation. Again, only a few of the patients, had a decreased 
secretion of α-granules compared to control platelets after activation by thrombin 
(n=2) or convulxin (n=2).  
 
Activation of GPIIb-IIIa receptor (detected by PAC1-binding) was evaluated after 
platelet activation by graded concentrations of ADP, convulxin and thrombin. Among 
patients with normal LTA-PRP, 4 out of 29 (14%) showed a decreased activation of 
the fibrinogen-receptor after ADP, 2/29 (7%) after thrombin, and 4/29 (14%) after 
convulxin. In the cohort with borderline LTA-PRP, 7 out of 38 (18%) patients showed 
a decreased GPIIb-IIIa activation after ADP, 6/38 (16%) after thrombin, and 7/38 
(18%) after convulxin. 
 
Procoagulant COAT platelets were generated by simultaneous platelet activation with 
convulxin and thrombin as already described in materials and methods. Overall, 16 
out of 67 (24%) patients showed a decreased procoagulant platelet activity (Table 2 
and Fig. 4). For comparison, the prevalence of COAT platelet levels <20% among 
normal controls employed for generating in-house cut-offs was 2/40 (p=0.024, Chi-
square; see Table 1) and 9/100 in platelet donors serving as daily controls for 
diagnostic FCA (p=0.015, Chi-square; median 27%; range 15% – 57%; 2.5th 
percentile 17% and 5th percentile 18%). 
  
For better visualization of the clustering of multiple defects in individual patients and 
in order to illustrate the relative frequency of potential platelet defects, we tabulated 
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the qualitative FCA results (white = normal; pale gray = borderline; dark gray = 
abnormal) together with the bleeding scores for each patient (Fig. 4). 
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Discussion 
Investigation of a bleeding diathesis includes several diagnostic steps and laboratory 
assays to identify its etiology (4,5). However, there is still a substantial percentage of 
patients having a positive bleeding diathesis in whom laboratory work-up is unable to 
detect a causative disorder (1).  
 
In this study we evaluated the diagnostic utility of an extensive phenotypic and 
functional characterization of platelets by flow cytometry in patients with a clinically 
significant bleeding diathesis but non-diagnostic standard laboratory investigations. 
 
We show that flow cytometric analysis (FCA) is able to identify several potentially 
explanatory platelet function defects (Table 2 and Fig. 4). However, we would also 
point out that among 18/67 patients (27%) FCA of platelet function was normal, 
indicating that either platelet defects not detectable by this technique or vessel wall 
defects could be responsible for the bleeding diathesis. 
 
First, we have identified dense-granule defects in 13 out of 67 patients (19%): in 8 
patients as an isolated anomaly and in 5 combined with other platelet function 
defects (Fig. 4). This observation confirms that symptomatic patients with normal 
platelet aggregation frequently have a storage pool disease (20,21) and is in line with 
the recommendation that platelet nucleotides content and release should specifically 
be investigated if aggregation studies are unrevealing (4,5). 
 
Second, we have observed some peculiar functional anomalies, which may point to 
the underlying specific defect. For instance, a single patient with an isolated 
impairment of GPIIb/IIIa activation with all agonists (#59 Fig. 4A), suggesting a 
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dysfunctional fibrinogen receptor. A patient with a decreased ADP-induced platelet 
activation (#22 Fig. 4B) and another with a reduced convulxin-induced activation (#64 
Fig. 4B), suggesting an involvement of the respective receptors. Other anomalies 
point to hypothetical defects in the pathways of specific agonist-induced activation 
end-points: for instance, secretion of α-granules by ADP (#15, #28, and #55 Figure 
4A and #46 Figure 4B) or convulxin (#05 Fig. 4A and #44 Fig. 4B), and activation of 
the fibrinogen-receptor induced by ADP (#32 Fig. 4A and #45, #48, #50 Fig. 4B), 
convulxin (#20 Fig. 4A and #27 and #19 Fig. 4B) or thrombin (#37 Fig 4B). It is 
reasonable to speculate, that these distinct clusters point to the underlying defect and 
that elucidation of the involved pathway may lead to the identification of the 
pathogenic mechanism.  
 
Third, we report that platelet α-granule secretion in response to the weak agonist 
ADP is more variable than that to thrombin or convulxin (Table 1) and that some 
patients show borderline results close to the cut-off values (Table 2). This is 
compatible with the hypothesis of minor platelet function defects, which are not 
detected by conventional platelet function studies but could lead to clinical relevant 
bleeding, especially if concomitant causes, such as surgical challenges, drugs or 
minor defects in other components of the hemostatic system are present (7). 
 
The fourth and to us most fascinating observation is that a substantial proportion of 
the investigated patient (16/67, 24%) show a decreased ability to produce COAT 
platelets (Table 2). COAT platelets are a subpopulation of platelets, generated by 
combined activation with collagen and thrombin, which are very effective in 
sustaining thrombin generation (16). COAT platelets retain high levels of α-granule 
proteins on their surface, including factor V, fibrinogen and von Willebrand factor 
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(VWF) by a serotonin- and transglutaminase-dependent mechanism (22). Among 
healthy individuals, Dale and his colleagues described, similarly to our results (Table 
1), an average of 33% COAT platelets and noted that the amount of an individual’s 
COAT platelets seems to be stable over time (19). 
 
The potential clinical relevance of COAT platelets in hemostasis is revealed by the 
work of Dale and Prodan. Their investigations have shown a link between COAT 
platelet level and the appearance of spontaneous intracerebral hemorrhages (23) 
and bleed volume (24). A low level of COAT platelets is also correlated with lacunar 
stroke morphology (18) and early hemorrhagic transformation in non-lacunar strokes 
(25). On the other hand, a high amount of COAT platelets seems to correlate with 
transient ischemic attack and ischemic stroke (26,27). Recently, the same group 
found a higher level of COAT platelets in patients with subarachnoid hemorrhage and 
described an increased 30-day mortality in association with the amount of COAT 
platelets in these patient population (28).  Finally, COAT platelets appear to have an 
impact on the bleeding phenotype in severe haemophilia (29). However, to draw 
robust conclusions about how individual differences in the level of COAT platelets 
contributes to a hemorrhagic or thrombotic phenotype, more clinical data are still 
required. 
 
In the present work we identified 16 out of 67 (24%) patients with a clinically 
significant bleeding diathesis but unrevealing laboratory work-up, who generated 
<20% COAT platelets. Of note, in the majority of them this was the only anomaly 
identified (n=10) and in the remainders it was usually associated with just a single 
additional platelet activation defect (Fig. 4). Since platelets of all 16 patients showed 
normal surface expression of negatively charged phospholipids upon activation with 
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ionophore A23187 this is not a primary defect in platelet procoagulant activity, such 
as in Scott Syndrome (30,31). We hypothesize that the impaired ability to generate 
procoagulant COAT platelets is likely to be secondary to an insufficient intracellular 
calcium rise upon combined activation with convulxin and thrombin. We are currently 
searching for causative defects (32).  
 
This work, showing a significantly higher prevalence of an impaired ability to generate 
COAT platelets in patients with a bleeding diathesis (16/67) than in normal controls 
(2/38 and 9/100; p=0.024 and 0.015, respectively) underscores the role of platelet 
procoagulant activity for the formation of a stable hemostatic plug. Of note, platelets 
ability to differentially regulate thrombin generation is an increasingly recognized 
aspect of hemostasis and thrombosis (33), beside their ability to adhere and 
aggregate. 
 
In perspective, COAT platelets could represent an interesting therapeutic target. If 
elevated COAT platelets will be shown to be independently associated with arterial 
thrombotic disease, drugs that specifically inhibit the mechanisms of platelet 
procoagulant transformation would result in potential new antithrombotic therapies. 
Conversely, up-regulating COAT platelet generation might be expected to represent 
a therapeutic option for patients suffering from bleeding diathesis (Colucci et al. 
Manuscript submitted). Finally, in vitro studies have shown that recombinant FVIIa 
preferentially binds to procoagulant platelets (34,35), and similar preferential binding 
to COAT platelets has been described for vatreptacog alfa, a novel recombinant 
FVIIa variant (36). Taking these data into account, the individual level of COAT 
platelets might be an important component for explaining the difference in hemostatic 
response to these drugs. 
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In summary, we show that phenotypic and functional platelet analysis by flow 
cytometry among patients with a significant bleeding diathesis and non-diagnostic 
standard laboratory work-up is able to identify potentially explanatory defect. We 
confirm that storage pool defects are frequent and should be searched in this 
population (in this report 19%). In addition, we show for the first time that a relevant 
proportion of these patients present with an isolated impairment of their ability to 
generate COAT platelets (in this report 24%). This is a conceptually novel (33), 
clinically potentially relevant defect in platelet procoagulant activity, that is missed by 
conventional laboratory work-up focusing on platelet adhesive and aggregating 
properties. 
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Table 1.  In house reference ranges for flow cytometric platelet function 
analysis (n=40) 
 
Parameter Indicator Unit Median 2.5
th
-percentile 5
th
-percentile In-house cut-off 
Size FSC MFI (*) 104 68 69 70 
Granularity SSC MFI (*) 102 82 82 80 
GPIIb Anti-CD41 mAb MFI (*) 102 84 87 80 
GPIIIa Anti-CD61 mAb MFI (*) 98 85 86 80 
GIb-alpha Anti-CD42b mAb MFI (*) 101 83 84 80 
Dense granules Mepacrine      
- content  MFI (*) 103 70 72 70 
- secretion (Thr 5 nM)  MFI (*) 100 96 97 90 
α-granule secretion Anti-CD62 mAb      
- Baseline  Absolute % 0.9   4 
- ADP 5 µM  MFI (*) 102 35 44 
40 
- ADP 50 µM  MFI (*) 99 39 40 
- Thrombin 0.5 nM  MFI (*) 100 65 70 
70 
- Thrombin 5 nM  MFI (*) 107 70 75 
- CVX 50 ng/ml  MFI (*) 99 67 68 
65 
- CVX 500 ng/ml  MFI (*) 106 67 67 
GPIIb/IIIa-activation PAC-1      
- Baseline  Absolute % 0.5   3 
- ADP 5 µM  MFI (*) 95 63 69 
70 
- ADP 50 µM  MFI (*) 94 65 72 
- Thrombin 0.5 nM  MFI (*) 111 58 60 
70 
- Thrombin 5 nM  MFI (*) 107 71 72 
- CVX 50 ng/ml  MFI (*) 98 57 58 
60 
- CVX 500 ng/ml  MFI (*) 98 58 61 
Procoagulant 
platelets 
Annexin-V   
   
- Baseline  Absolute % 1.9   5 
- COAT platelets  Absolute % 31 19 20 20 
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Legend: ADP, adenosine diphosphate; CVX, convulxin; FSC, forward scatter; mAb, 
monoclonal antibody; MFI = median fluorescence intensity; SSC, sideward scatter; 
Thr, thrombin; (*) = relative to control platelets 
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Table 2. Patient characteristics and type of platelet dysfunction revealed by 
flow-cytometric analysis (FCA) in patients with significant bleeding diathesis 
and non-diagnostic standard laboratory workup (n = 67). 
 
 
 
(see next page) 
 
 
 
†, borderline values are defined as lying within 3% above the cut-off level 
*, individual results 
 
Legend: ADP, adenosine diphosphate; FCA, flow-cytometric analysis; GPIIb/IIa, 
Glycoprotein IIb/IIIa-receptor; ISTH, International Society on Thrombosis and 
Hemostasis; LTA-PRP, light transmission aggregometry in platelet-rich plasma; UCH, 
University Clinic for Haematology, Inselspital, Bern 
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Patients with normal LTA-PRP Patients with borderline LTA-PRP 
Total number of patients (n, %) 29 (43%) 38 (57%) 
Sex (women/men) 24/5 26/12 
Age (years, median, min/max) 52.8 (23.5/75.4) 43.2 (16.8/72.9) 
Bleeding score UCH (median, min/max) 6 (3/17) 4 (1/19) 
Bleeding score ISTH (median, min/max) 6 (1/14) 4 (0/16) 
Platelet FCA findings (n, %)   
Normal 10 (35%)   8 (21%) 
Borderline (
†
)   1 (3%)   1 (<3%) 
Abnormal 18 (62%) 29 (76%) 
Delta storage pool disease 
  
Dense-granule content (<70%) 3 (54%, 57%, 67%)* 6 (57%, 60%, 63%, 66%,  66%, 68%)* 
Dense-granule content (borderline
†
) 0 3 (70%, 71%, 71%) 
Dense-granule secretion, thrombin (<90%) 3 (51%, 82%, 89%)* 2 (76%, 88%)* 
Dense-granule secretion, thrombin (borderline
†
) 1 (92%)* 1 (92%)* 
Decreased α-granules secretion 
  
ADP (<40%) 5 (24%, 26%, 28%, 37%, 39%)* 5 (31%, 32%, 36%, 36%, 37%)* 
ADP (borderline
†
) 2 (42,%, 42%)* 0 
Thrombin (<70%) 1 (66%)* 2 (65%, 69%)* 
Thrombin (borderline
†
) 0 0 
Convulxin (<65%) 2 (53%, 63%)* 2 (46%, 49%)* 
Convulxin (borderline
†
) 0 1 (65%)* 
Decreased GPIIb/IIIa-receptor activation 
  
ADP (<70%) 4 (62%, 64%, 64%, 66%)* 7 (47%, 52%, 56%, 63%, 64%, 65%, 67%)*  
ADP (borderline
†
) 1 (70%)* 3 (70%, 70%, 72%)* 
Thrombin (<70%) 2 (49%, 53%)* 6 (50%, 53%, 63%, 65%, 66%, 66%)*   
Thrombin (borderline
†
) 0 2 (71%, 71%)* 
Convulxin (<60%) 4 (45%, 51%, 52%, 57%)* 7 (33%, 45%, 49%, 56%, 57%, 57%, 58%)* 
Convulxin (borderline
†
) 0 0 
Procoagulant COAT platelets   
Thrombin + Convulxin (<20%) 
7 (13%, 13%, 15%, 16%, 16%, 
     17%, 19%)* 
9 (9%, 11%, 13%, 15%, 16%, 17%, 18%, 
    19%, 19%)* 
Thrombin + Convulxin (borderline
†
) 1 (21%)* 2 (21%, 22%)* 
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Figure legends 
 
Figure 1. Diagnostic flow-chart for patients with bleeding diathesis. 
The flow chart describes the standardized procedure with step by step diagnostic 
work-up of out-patients referred to our institution for clarification of a bleeding 
diathesis. 
 
Figure 2. Flow-cytometric analysis of platelet phenotype and function 
Flow-cytometric analysis of platelet function was performed as described in the 
Methods section. Panel A: Resting platelets stained for GPIIb (CD41) and P-Selectin 
(CD62). Panel B: Surface expression of GPIIIa (CD61) and GPIbα (CD42b) on 
resting platelets. Panel C: Dense granule content and secretion (Dotted line: 
unstained platelets; interrupted line, platelets loaded with mepacrine 1.7 µM; 
continuous line: mepacrine-loaded platelets after activation with 5nM thrombin). 
Panel D: Platelet procoagulant activity (Dotted line: resting platelets; interrupted line: 
platelets activated with ionophore A 23187; continuous line: platelets simultaneously 
activated with convulxin 500 ng/ml and thrombin 5 nM, the bar highlights COAT 
platelets). 
 
Figure 3. Flow-cytometric analysis of agonist-induced platelet activation 
Flow-cytometric analysis of platelet function was performed as described in the 
Methods section. Panel A: Resting platelets stained with PAC-1 (recognizing an 
activation-dependent conformational change of the fibrinogen-receptor, GPIIb/IIIa) 
and anti-CD62 mAb (detecting surface-expression of P-selectin, a marker of α-
granule secretion). Platelets after activation with graded concentrations of thrombin 
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(Panel B: 0.5 nM; Panel C: 5 nM) or convulxin (Panel D: 5 ng/ml, Panel E: 50 ng/ml, 
Panel F: 500 ng/ml). 
 
Figure 4. Synoptic overview of FCA results of platelet function in 67 patients 
with clinically significant bleeding diathesis and non-diagnostic standard 
laboratory work-up. 
Panel A: Patients with normal LTA-PRP. Panel B: Patients with borderline LTA-PRP. 
Each row represents one single patient with its study number, hypothetical defect and 
bleeding scores. Endpoint/agonist combinations are shown in different lanes and 
individual FCA results (%) are displayed. Agonist-response below in-house cut-offs 
(Table 1) is marked as a dark-gray box; borderline agonist response (Table 2) is 
labeled as a pale-gray box; normal response is left in white. “Defect?” indicates the 
hypothetical underlying platelet function defect: e.g., GPIIb/IIIa (CVX): pathway 
involved in convulxin-induced activation of the fibrinogen-receptor; Alpha (ADP): 
pathway involved in ADP-induced secretion of α-granules; Dense: storage-pool 
disease. 
 
Abbreviations: ADP, adenosine diphosphate; BS, bleeding score; CVX, convulxin; 
FCA, flow cytometric analysis; GPVI, collagen receptor; ISTH, International Society 
on Thrombosis and Hemostasis; mepa, mepacrine; P2Y1 and P2Y12, ADP receptors; 
PAC-1, antibody that recognizes an activation-dependent epitope on GPIIb-IIIa 
(integrin αIIbβ3); UCH, University Clinic of Hematology, Inselspital, Bern. 
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Figure 1 
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+ 
Full blood count, global coagulation tests, 
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Pathologic bleeding score 
and/or 
laboratory examinations 
No further diagnostic work up: 
no intrinsic cause for index bleeding 
episode 
Light transmission platelet 
aggregation testing (LTA) 
in platelet rich plasma (PRP)  
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Figure 2 
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Figure 2A 
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Figure 2B 
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Figure 2C 
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Figure 2D 
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Figure 3 
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Figure 3A 
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Figure 3B 
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Figure 3C 
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Figure 3D 
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Figure 3E 
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Figure 3F 
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Figure 4A 
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Figure 4B 
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Supplemental Table 1. 
Characteristics of patients with clinically significant bleeding diathesis and 
non-diagnostic standard laboratory work-up (n = 67). 
  
  Normal LTA-PRP  Borderline LTA-PRP  p  
        
Total number of patients  29  38  ---  
        
Sex (women/men)  24/5  26/12  ---  
        
Age (years, median, min/max)  52.8 (23.5/75.4)  43.2 (16.8/72.9)    
        
Bleeding score UCH (median, min/max)  6 (3/17)  4 (1/19)  ns  
Bleeding score ISTH (median, min/max)  6 (1/14)  4 (0/16)  ns  
        
Coagulation parameters (normal range)  Median (min/max)  Median (min/max)  p  
 item                         unit       normal range        
 VWF:RCo                  %            42-168      89.0        (47.0/260.0)        82.5       (55.0/165.0)  ns  
 VWF:Ag                     %             42-136      89.0        (50.0/235.0)        82.5       (55.0/150.0)  ns  
 VWF:ratio                                     > 0.7      1.0          (0.7/1.3)        1.0         (0.7/1.2)  ns  
 FVIII:C                       %             55-164      96           (63/152)        87          (65/145)  ns  
 FIX:C                         %             69-134      98           (70/130)       100         (74/212)  ns  
 FXI:C                         %             70-139      100         (71/135)       103         (74/134)  ns  
 FXIII qualitative      normal     normal  ns  
 FXIII activity               %            70-140      104         (62/135)*       106         (73/179)†  ns  
α-2-Antiplasmin           %            73-126      107         (80/129)       112         (89/130)  ns  
PFA ADP/collagen     sec           65-121      104         (65/211)       105         (70/185)  ns  
PFA Epi/collagen       sec           91-157      145         (83/300)       151         (74/246)  ns  
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Abbreviations: pts, patients; LTA-PRP, light transmission aggregometry in platelet-
rich plasma; SD, standard deviation; UCH, University Clinic Haematology, Bern; 
ISTH, International Society of Thrombosis and Haemostasis; VWF:RCo, von-
Willebrand-Ristocetin-Cofactor; VWF:Ag, von-Willebrand-Antigen; VWF:ratio, von-
Willebrand-Factor-ratio; PFA, platelet function analyzer-100 closure time; Epi; 
epinephrine; sec, seconds; ns, not significant. *, FXIII activity was measured in 7/29 
patients. †, FXIII activity was measured in 12/38 patients. 
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Questionnaire for bleeding diathesis 
“UCH-bleeding score” 
Department of Hematology and Central Hematology Laboratory  
University Hospital, Inselspital Bern Switzerland 
 
 
1. Cutaneous symptoms Point(s): 
• No bruising/no hematoma, except after adequate trauma; no petechiae. 0 
Occasional minor bruising after a mild insult, especially in women, is still normal. 
 
• Occasional minor bruising/hematoma without memory of any trauma  1 
or 
one time or occasional appearance of larger hematoma without any appropriate trauma. 
 
• Often multiple bruising without memory of any trauma 2 
or 
frequent petechiae/hematoma along with solitary bruising events 
or 
repeated large hematoma without any trauma or with only very mild trauma. 
 
(petechiae alone, without other signs of hemorrhagia, should be described in 11.) 
 
2. Epistaxis 
• No or rare epistaxis events (< 2x per year), duration < 15 minutes,  0 
hemostatic treatment effective with commonly used household methods.  
 
• Occasional epistaxis (> 3x per year), duration > 15 but < 30 minutes, 1 
hemostatic treatment effective with commonly used household methods. 
No underlying local anatomic problem known. 
 
• Frequent epistaxis (> 1x every 2 months), duration often > 30 minutes, 2 
specific medical treatment for hemostasis necessary in some cases, including 
transfusion of blood products. No underlying local anatomic problem known. 
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3. Oral cavity (without dental treatment) Point(s): 
• No bleeding signs of the gingiva or elsewhere in the oral cavity except in case  
of using a new/hard toothbrush. 0 
 
• Occasional gingival bleeding independent of tooth cleaning. 1 
 
• Often and/or repeated strong bleeding of the gingiva or elsewhere in the 2 
oral cavity. Medical treatment for hemostasis necessary. 
or 
Many petechiae of the oral mucosa without a known underlying medical or  
anatomic cause (e.g. Morbus Rendu-Weber-Osler). 
 
4. Bleeding signs/complications during/after dental treatment/maxillary surgery 
• No bleeding signs during or after dental treatment/maxillary surgery. 0 
 
• One bleeding complication over several hours during/after dental treatment/ 1 
maxillary surgery. 
 
• Repeated (> 2x) bleeding complications over several hours, with necessity 2 
of dental re-treatment/maxillary re-surgery. 
 
5. Bleeding after minor injury 
• No prolonged bleeding after a cut-wound or abrasion; bleeding stops 0 
in less than 10 minutes either spontaneously or by using a small bandage. 
 
• Occasional prolonged bleeding following minor wounds; treatment with small 1 
bandage results in bleeding cessation. 
 
• Recurrence of prolonged and greater bleeding complications after minor 2 
wounds, regular bandage not sufficient for bleeding cessation. Additional specific 
hemostatic treatment required. 
 
6. Muscle hematomas or hemarthroses 
• No muscle hematomas or hemarthroses except after severe injury. 0 
 
• One episode of muscle hematoma or hemarthroses either spontaneously or 1 
after inadequate trauma. 
 
• Several (> 2x) episodes of muscle hematomas or hemarthroses, 2 
spontaneously or after inadequate trauma, and without underlying medical or 
anatomic cause. Degenerative arthropathy as long-term consequence. 
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7. Bleeding of the gastrointestinal tract or genitourinary tract Point(s): 
• No bleeding events or only bleeding events due to an underlying local cause. 0 
 
• Gastrointestinal or genitourinary bleeding of unknown etiology. 1 
Prolonged and/or strong bleeding, e.g. in the case of hemorrhoids. 
 
• Recurrent gastrointestinal or genitourinary bleeding episodes without 2 
pathological findings and not drug-induced. 
 
8. Menorrhagia 
• Regular menstrual bleeding (duration of 3-5 days, 2-5 pads/tampons per day). 0 
 
• Possible or distinct symptoms of menorrhagia/hypermenorrhea without 1 
definite exclusion of an underlying gynecological cause. 
 
• Severe menorrhagia (duration > 7 days) or hypermenorrhea (replacement of 2 
pads/tampons even during night time) without underlying gynecological cause. 
 
9. Bleeding complications during/after surgery 
• No bleeding complications during/after surgery. No need for transfusions. 0 
 
• One single episode of bleeding complication during/after surgery. 1 
 
• Several (> 2x) bleeding episodes during/after surgeries with excessive 2 
bleeding, requiring transfusions, suture or re-surgery.  
 
10. Transfusions 
• No need for transfusions, except for large surgical interventions or injuries.  0 
 
• One single episode of transfusion during/after minor surgical intervention or 1 
due to minor injury. 
 
• Several (> 2) episodes of transfusions during/after minor surgical interventions 2 
or after minor injuries. 
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11. Bleeding complications of unknown origin/reason Point(s): 
• No episode. 0 
 
• Major bleeding complication/organ bleeding without clarification of underlying 1 
cause. 
 
• Major bleeding complication/organ bleeding of unknown reason after adequate 2 
medical examination. 
 
12. Bleeding diathesis linked to medication intake (e.g. NSAIDs, aspirin) 
• No bleeding diathesis after medication intake. 0 
 
• Doubtful correlation of bleeding diathesis and medication intake. 1 
 
• Definite correlation of bleeding diathesis and medication intake. 2 
 
13. Hereditary reasons for bleeding diathesis 
• No bleeding diathesis in the patient’s family. 0 
 
• Suspicious positive bleeding diathesis for one or more members in the 1 
patient’s family. 
 
• Definite positive bleeding diathesis for one or more members in the 2 
patient’s family. 
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